Vaccinex logo
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023 09:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Global Cancer Vaccine Market to Generate USD 13.41 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
May 03, 2023 09:00 ET | Next Move Strategy Consulting
New York, May 03, 2023 (GLOBE NEWSWIRE) -- According to a report published by Next Move Strategy Consulting, the global Cancer Vaccine Market generated USD 5.75 billion in 2022 and is projected to...